ResearcherUniversity of ZurichNo recent work listed
Gerald Schwank
Matched on ORCID iD 0000-0003-0767-2953; OpenAlex author ID A5016124492. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 12
2021: 1 paper · 2022: 3 papers · 2023: 2 papers
Papers 6
- Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. Co-author DOI 10.1016/j.isci.2023.107368↗
- Mutant SF3B1 promotes malignancy in PDAC. Last author DOI 10.7554/elife.80683↗
- SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. Last author DOI 10.1016/j.celrep.2022.111266↗
- Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Last author DOI 10.1016/j.xgen.2022.100095↗
- Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing. Last author DOI 10.1038/s41467-022-29412-3↗
- Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding isoform of SLC35A3 Co-author DOI 10.1016/j.ygeno.2020.12.039↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Markus Stoffel · 3 shared papers, 2022–2023 · strength 0.43
- Paper Mutant SF3B1 promotes malignancy in PDAC. DOI 10.7554/elife.80683↗
- Paper Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. DOI 10.1016/j.isci.2023.107368↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
- Gunnar Rätsch · 3 shared papers, 2021–2023 · strength 0.41
- Paper Mutant SF3B1 promotes malignancy in PDAC. DOI 10.7554/elife.80683↗
- Paper Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding… DOI 10.1016/j.ygeno.2020.12.039↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
- Patrik Simmler · 3 shared papers, 2022–2023 · strength 0.38
- Paper Mutant SF3B1 promotes malignancy in PDAC. DOI 10.7554/elife.80683↗
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
- Christian Hirt · 3 shared papers, 2021–2022 · strength 0.36
- Paper Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding… DOI 10.1016/j.ygeno.2020.12.039↗
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266↗
- Ilaria Guccini · 2 shared papers, 2022–2023 · strength 0.26
- Chantal Pauli · 2 shared papers, 2022 · strength 0.22
- Daniela M. Lenggenhager · 2 shared papers, 2022 · strength 0.22
- Nina Frey · 1 shared paper, 2022 · strength 0.16
- Solange Le Blanc · 1 shared paper, 2023 · strength 0.15
- Oliver Strobel · 1 shared paper, 2023 · strength 0.15
- Philipp Markolin · 1 shared paper, 2021 · strength 0.14
- Hagen Klett · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.